Abstract
The past decade has seen many exciting achievements and advances in the treatment of HIV infection. One of the key components in this ever-evolving remedial strategy has been medicinally efficacious enzymatic inhibitors targeting the essential viral aspartyl protease. While the use of currently approved HIV protease inhibitors in concert with drugs that target the reverse transcriptase has dramatically ameliorated the disease state for many individuals, highly-structured dosing regimens accompanied by adverse side-effect profiles have led to a significant level of patient non-compliance. In addition, the development of and selection for resistant mutants have limited the long-term therapeutic outlook of the current protease inhibitors. The need for complementary agents in this salutary class addressing these challenges and opportunities is vividly clear. To this end, much attention and focus has been placed on cyclic, non-peptidic protease inhibitors, exemplified by dihydropyrones and ureas, and their possible future role in this medicinal campaign. The strategies to their design as well as their biological, pharmacokinetic and resistance profiles, and their clinical application will be discussed.
Keywords: aids, cyclic urea, dihydropyrone, hiv, non-peptidic protease inhibitor, protease inhibitor
Current Topics in Medicinal Chemistry
Title: Non-Peptidic HIV Protease Inhibitors
Volume: 4 Issue: 10
Author(s): R. Alan Chrusciel and Joseph W. Strohbach
Affiliation:
Keywords: aids, cyclic urea, dihydropyrone, hiv, non-peptidic protease inhibitor, protease inhibitor
Abstract: The past decade has seen many exciting achievements and advances in the treatment of HIV infection. One of the key components in this ever-evolving remedial strategy has been medicinally efficacious enzymatic inhibitors targeting the essential viral aspartyl protease. While the use of currently approved HIV protease inhibitors in concert with drugs that target the reverse transcriptase has dramatically ameliorated the disease state for many individuals, highly-structured dosing regimens accompanied by adverse side-effect profiles have led to a significant level of patient non-compliance. In addition, the development of and selection for resistant mutants have limited the long-term therapeutic outlook of the current protease inhibitors. The need for complementary agents in this salutary class addressing these challenges and opportunities is vividly clear. To this end, much attention and focus has been placed on cyclic, non-peptidic protease inhibitors, exemplified by dihydropyrones and ureas, and their possible future role in this medicinal campaign. The strategies to their design as well as their biological, pharmacokinetic and resistance profiles, and their clinical application will be discussed.
Export Options
About this article
Cite this article as:
Chrusciel Alan R. and Strohbach W. Joseph, Non-Peptidic HIV Protease Inhibitors, Current Topics in Medicinal Chemistry 2004; 4 (10) . https://dx.doi.org/10.2174/1568026043388312
DOI https://dx.doi.org/10.2174/1568026043388312 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Effects of Insulin and Insulin-Like Growth Factors on Tumor Vascularization: New Insights of Insulin-Like Growth Factor Family in Cancer
Current Medicinal Chemistry Rheumatoid Arthritis Patients with Sjogrens Syndrome are More Prone to Depression than Patients with Rheumatoid Arthritis or Sjogrens Syndrome Alone
Current Rheumatology Reviews Nanocarriers in Improved Heparin Delivery: Recent Updates
Current Pharmaceutical Design The Relevance of Peripheral Immune Tolerance in Normal Pregnancy and its Potential Failure in Gestation-Associated Diseases
Current Women`s Health Reviews Patent Selections
Recent Patents on Biotechnology Reactive Oxygen Species in the Initiation of IL-4 Driven Autoimmunity as a Potential Therapeutic Target
Current Pharmaceutical Design Synthetic Lethality and PARP-Inhibitors in Oral and Head & Neck Cancer
Current Pharmaceutical Design MDMA and Impulsivity: A Review
Current Psychiatry Reviews Wound-Associated Skin Fibrosis: Mechanisms and Treatments Based on Modulating the Inflammatory Response
Endocrine, Metabolic & Immune Disorders - Drug Targets Synthetic Lethality to Overcome Cancer Drug Resistance
Current Medicinal Chemistry Body Mass Index, Lipid Metabolism and Estrogens: Their Impact on Coronary Heart Disease
Current Medicinal Chemistry Nanomedicines as Therapeutics in HIV-AIDS
Pharmaceutical Nanotechnology RNA Interference as a Tool for Alzheimers Disease Therapy
Mini-Reviews in Medicinal Chemistry Modeling Follicle Stimulating Hormone Levels in Serum for Controlled Ovarian Hyperstimulation I: Comparing Gonadotropin Products
Current Pharmaceutical Biotechnology Insights Into Nicotinic Receptor Signaling in Nicotine Addiction: Implications for Prevention and Treatment
Current Neuropharmacology Neuroimaging of the Serotonin Transporter: Possibilities and Pitfalls
Current Psychiatry Reviews The Role of P2Y<sub>12</sub> Receptor and Activated Platelets During Inflammation
Current Drug Targets The Changing Landscape of Voltage-Gated Calcium Channels in Neurovascular Disorders and in Neurodegenerative Diseases
Current Neuropharmacology The Renin-Angiotensin System: Emerging Concepts
Current Hypertension Reviews Recent Advances in Copper Radiopharmaceuticals
Current Radiopharmaceuticals